MediciNova (MNOV) director receives grant of 44,500 stock options

Rhea-AI Filing Summary

MediciNova Inc. director Carolyn Beaver received a stock option grant covering 44,500 shares of common stock. The options have an exercise price of $1.36 per share and expire on June 22, 2036. The award vests in four equal installments on September 30, 2026, December 31, 2026, March 31, 2027, and June 30, 2027, subject to her continued service with the company. After this grant, she holds 44,500 derivative securities (options). This is a compensation-related award rather than an open-market share purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider BEAVER CAROLYN

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	44,500	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 44,500 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 44,500 options Exercise price: $1.36 per share Expiration date: June 22, 2036 +1 more

4 metrics

Option grant size 44,500 options Stock Option (Right to Buy) granted to director Carolyn Beaver

Exercise price $1.36 per share Conversion or exercise price of the stock options

Expiration date June 22, 2036 Option expiration date for the granted stock options

Shares underlying options 44,500 shares Underlying MediciNova common stock linked to the option grant

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, vests in four equal installments

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 1.3600"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-22T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vests in four equal installments financial

"The option vests in four equal installments on September 30, 2026, December 31, 2026, March 31, 2027 and June 30, 2027"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/25/2026 - 04:35 PM Accepted by SEC EDGAR 06/25/2026 - 04:35 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BEAVER CAROLYN

(Last) (First) (Middle)

C/O MEDICINOVA, INC.

4275 EXECUTIVE SQUARE, SUITE 300

(Street)

LA JOLLA CALIFORNIA

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MEDICINOVA INC [ MNOV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.36	06/23/2026		A		44,500		(1)	06/22/2036	Common Stock	44,500	$0	44,500	D

Explanation of Responses:

1. The option vests in four equal installments on September 30, 2026, December 31, 2026, March 31, 2027 and June 30, 2027, subject to continued service with the Company.

	/s/ Yuichi Iwaki, attorney-in-fact	06/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did MediciNova (MNOV) report for Carolyn Beaver?

MediciNova reported that director Carolyn Beaver received a stock option grant for 44,500 shares of common stock. This is a compensation-related award, not an open-market trade, and reflects equity-based incentives tied to her continued service on the board.

How many MediciNova (MNOV) options were granted to Carolyn Beaver and at what price?

Carolyn Beaver was granted stock options covering 44,500 shares of MediciNova common stock at an exercise price of $1.36 per share. She can purchase shares at this price once the options vest, if she chooses to exercise them.

When do Carolyn Beaver’s MediciNova (MNOV) stock options vest?

The stock options granted to Carolyn Beaver vest in four equal installments on September 30, 2026, December 31, 2026, March 31, 2027, and June 30, 2027. Vesting is conditioned on her continued service with MediciNova through those dates.

What is the expiration date of Carolyn Beaver’s MediciNova (MNOV) stock options?

Carolyn Beaver’s stock options expire on June 22, 2036. If unexercised by that date, the options will lapse. The long expiration term gives her a substantial window to decide whether to exercise her rights to purchase shares.

Did Carolyn Beaver buy or sell MediciNova (MNOV) shares in the market?

No, the Form 4 shows a grant of stock options as compensation, not an open-market purchase or sale of MediciNova shares. The transaction is coded as a grant/award acquisition rather than a buy or sell in the public market.

How many MediciNova (MNOV) derivative securities does Carolyn Beaver hold after this grant?

After this grant, Carolyn Beaver holds 44,500 derivative securities, all from this stock option award. These options give her the right, but not the obligation, to purchase an equal number of MediciNova common shares at $1.36 per share.